{"id":4664,"date":"2025-03-31T18:12:16","date_gmt":"2025-03-31T18:12:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ritonavir-txt\/"},"modified":"2025-03-31T18:12:16","modified_gmt":"2025-03-31T18:12:16","slug":"ritonavir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ritonavir-txt\/","title":{"rendered":"ritonavir.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nProtease inhibitor:Treatment of HIV-1 infection in combination other antiretrovirals

DOSE IN NORMAL RENAL FUNCTION <\/H3>600 mg twice dailyAs low dose booster with other protease inhibitors: 100\u2013200 mg once or twice daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :720.9<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :98\u201399<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 3.5<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.4<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :3\u20135\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Not dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAlfuzosin: avoid concomitant use\n
  • Analgesics: opioid and NSAID levels may be increased (risk of toxicity) \u2013 avoid dextropropoxyphene and piroxicam; methadone and pethidine levels reduced; increased fentanyl and toxic pethidine metabolite concentration \u2013 avoid with pethidine\n
  • Anti-arrhythmics: increased concentration of amiodarone, flecainide and propafenone (increased risk of ventricular arrhythmias) \u2013 avoid concomitant use; possible increased risk of arrhythmias with disopyramide and mexiletine\n
  • Antibacterials: rifabutin concentration increased (risk of uveitis) \u2013 avoid; concentration of clarithromycin and other macrolides increased \u2013 reduce dose of clarithromycin in renal impairment; concentration of both drugs may be increased in combination with fusidic acid; avoid with telithromycin in renal and hepatic failure\n
  • Anticoagulants: anticoagulant effect of coumarins and phenindione possibly increased; effect of warfarin may be enhanced or reduced\n
  • Antidepressants: SSRIs and tricyclic concentrations possibly increased; concentration reduced by St John\u2019s wort; possibly reduced paroxetine concentration; increased side effects with trazodone\n
  • Anti-epileptics: carbamazepine and phenytoin concentration may be increased; concentration reduced by phenytoin\n
  • Antifungals: in combination with itraconazole or ketoconazole concentration of both drugs may be increased; concentration increased by fluconazole; voriconazole concentration reduced \u2013 avoid\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: concentration of pimozide, sertindole, clozapine and possibly other antipsychotics may be increased (risk of toxicity) \u2013 avoid concomitant use; possibly inhibits metabolism of aripiprazole \u2013 reduce aripiprazole dose; olanzapine concentration reduced\n
  • Antivirals: levels of both nelfinavir and ritonavir may be increased if used in combination; amprenavir, indinavir and saquinavir levels increased; increased risk of toxicity with efavirenz \u2013 monitor LFTs
    Anxiolytics and hypnotics: levels of many of them increased (risk of extreme sedation and respiratory depression) \u2013 avoid alprazolam, diazepam, flurazepam, midazolam, zolpidem; concentration of buspirone increasedBupropion: bupropion levels increased (risk of toxicity) \u2013 avoid\n
  • Calcium-channel blockers: levels of blockers possibly increased \u2013 avoid with lercanidipine.\n
  • Ciclosporin: levels possibly increased by ritonavir
    Cilostazol: concentration of cilostazol possibly increased \u2013 avoid concomitant use
    Corticosteroids: possibly increased corticosteroid concentration; increased concentration of inhaled\/intranasal budesonide and fluticasone\n
  • Diuretics: eplerenone concentration increased \u2013 avoid concomitant use\n
  • Ergot alkaloids: risk of ergotism \u2013 avoid Ivabradine: ivabradine concentration possibly increased \u2013 avoid concomitant useLipid-lowering drugs: increased risk of myopathy with simvastatin \u2013 avoid; possibly increased risk of myopathy with atorvastatin
    Oestrogens and progestogens: metabolism accelerated (contraceptive effect reduced)5HT 1 agonists: concentration of eletriptan increased \u2013 avoidSildenafil: concentrations of sildenafil significantly increased \u2013 avoid
    Theophylline: metabolism accelerated, theophylline levels reduced\n
  • Tacrolimus: levels possibly increased by ritonavir\n
  • Vardenafil: possibly increased vardenafil concentration \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Administer with food .
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Protease inhibitor:Treatment of HIV-1 infection in combination other<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4664","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4664"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4664\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}